Stopping treatment at two years does not seem to compromise overall survival in patients with advanced lung cancer
Can't see this email? View it online
   
  Oncology  
  The latest oncology news from News Medical  
 Study sheds light on metabolic enzymes and processes essential for DNA damage repairStudy sheds light on metabolic enzymes and processes essential for DNA damage repair
 
In crisis, the nucleus calls antioxidant enzymes to the rescue. The nucleus being metabolically active is a profound paradigm shift with implications for cancer research.
 
 
 Stopping treatment at two years does not seem to compromise overall survival in patients with advanced lung cancerStopping treatment at two years does not seem to compromise overall survival in patients with advanced lung cancer
 
Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival for the disease.
 
   Study suggests possible new treatment option for people with slow-growing but deadly brain tumorStudy suggests possible new treatment option for people with slow-growing but deadly brain tumor
 
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening.
 
   SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphomaSWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma
 
A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.
 
   Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCOFred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO
 
At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances in treatments and clinical trials, how access to cancer care affects outcomes, integrative medicine and more.
 
 Study finds substantial differences in cancer drug funding decisions across high-income countries
 
Study finds substantial differences in cancer drug funding decisions across high-income countriesDespite the use of similar assessment criteria when deciding whether new cancer drugs should receive funding, there are substantial differences in drug funding decisions, across comparable high-income countries.
 
 
 Breast cancer patients experience more severe CIPN symptoms with paclitaxel
 
Breast cancer patients experience more severe CIPN symptoms with paclitaxelChemotherapy-induced peripheral neuropathy (CIPN) – nerve pain, tingling, or numbness in the hands or feet – is a common side effect of certain cancer treatments, including two drugs frequently used to treat cancer – the taxanes paclitaxel and docetaxel.
 
 
 Extended lymphadenectomy for locally advanced bladder cancer provides no patient benefit
 
Extended lymphadenectomy for locally advanced bladder cancer provides no patient benefitAn extended lymphadenectomy – removal of additional lymph nodes beyond the extent of the standard procedure – in patients undergoing radical cystectomy (removal of bladder and nearby tissues) because of clinically localized muscle-invasive bladder cancer provides no patient benefit as measured by disease-free survival or overall survival times.
 
 
 Phase III ZUMA-7 trial: Patients with high-risk large B-cell lymphoma lived longer with axi-cel
 
Phase III ZUMA-7 trial: Patients with high-risk large B-cell lymphoma lived longer with axi-celPatients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
 
 
 Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer
 
Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancerUpdated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d'Hebron Institute of Oncology's (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), 2-6 June in Chicago, USA.
 
 
 Expertise in cancer treatment could be used to find a cure for endometriosis
 
Expertise in cancer treatment could be used to find a cure for endometriosisEndometriosis: If we utilize all the knowledge we have about cancer, there is reason to hope that effective diagnosis and treatments can be developed to combat the female condition 'everybody' is talking about.
 
 
 Clinical trials demonstrate positive results from targeted therapy for patients with multiple tumor types with FGFR alterations
 
Clinical trials demonstrate positive results from targeted therapy for patients with multiple tumor types with FGFR alterationsThree clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations.
 
 
 Smoking cessation among cancer survivors linked to lower cardiovascular risk
 
Smoking cessation among cancer survivors linked to lower cardiovascular riskCancer patients who continue smoking after their diagnosis have a nearly doubled risk of heart attack, stroke or death due to cardiovascular disease compared with non-smokers, according to research published on World No Tobacco Day in European Heart Journal, a journal of the European Society of Cardiology.
 
 
 Novel approach improves the efficacy of immune checkpoint blockade and minimizes related side effects
 
Novel approach improves the efficacy of immune checkpoint blockade and minimizes related side effectsScientists at Tohoku University have discovered a novel approach that improves the efficacy of immune checkpoint blockade (ICB) - a novel form of cancer treatment utilizing immune checkpoint inhibitors (ICIs) - and minimizes the associated side effects.
 
 
 New data guides treatment choices for patients with r/r lymphoma during pregnancy
 
New data guides treatment choices for patients with r/r lymphoma during pregnancyToday, Blood Advances published a study revealing that patients with relapsed/refractory (r/r) lymphoma during pregnancy experienced a progression-free survival rate of 24% and an overall survival rate of 83%.
 
 
 NCI launches new initiative to test new drug combinations that target specific tumor alterations
 
NCI launches new initiative to test new drug combinations that target specific tumor alterationsThe National Cancer Institute (NCI) has launched a large precision medicine cancer initiative to test the effectiveness of treating adults and children with new drug combinations that target specific tumor alterations.
 
 
 Researchers create an open-source, reproducible analysis platform for pediatric brain tumors
 
Researchers create an open-source, reproducible analysis platform for pediatric brain tumorsResearchers from Children's Hospital of Philadelphia, the Alex's Lemonade Stand Foundation Childhood Cancer Data Lab, the Children's Brain Tumor Network, the Pacific Pediatric Neuro-Oncology Consortium, and more than 20 additional institutions have partnered to create a first-of-its-kind open-source, reproducible analysis platform for pediatric brain tumors.